Read Summary

Interleukin 6 may be a biomarker for distant recurrence of breast cancer among patients treated for stage II-III HER2-negative disease, investigators have found. The evidence was presented at ASCO 2021.
Medscape Medical News

Print Friendly, PDF & Email